Erratum: Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline (The Journal of Clinical Endocrinology and Metabolism (2013) 98:12 (4565-4592) DOI: 10.1210/jc.2013-2350);Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4565-4592

  Legro, Richard S ^a   Arslanian, Silva A ^b   Ehrmann, David A ^c   Hoeger, Kathleen M ^d   Murad, M Hassan ^e   Pasquali, Renato ^f   Welt, Corrine K ^g  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CLOMIFENE CITRATE; CONTRACEPTIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TROGLITAZONE;

ACNE; ALOPECIA; AMENORRHEA; ANOVULATION; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLIMACTERIUM; DEPRESSION; ENDOMETRIUM CANCER; EVIDENCE BASED PRACTICE; EXERCISE; FAMILY HISTORY; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIVER TOXICITY; LOW CALORY DIET; MENOPAUSE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OLIGOMENORRHEA; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; SOCIETIES, SCIENTIFIC;

EID: 84889798433     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgab248     Document Type: Erratum

References (296)

1. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93: 1105-1120
2. Rosenzweig JL, Ferrannini E, GrundySM,et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3671-3689
3. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use. MMWR Recomm Rep. 2010;59:1- 86
4. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490
5. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673
6. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Haseltine G, eds. Polycystic Ovary Syndrome. 1st ed. Oxford, England: Blackwell Scientific; 1992:377-384
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47
8. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462-477
9. Azziz R, Carmina E, Dewailly D, et al Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009;91:456-488
10. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000;160:1573-1575
11. Melmed S, Casanueva FF, Hoffman AR, et al Endocrine Society. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:273-288
12. Speiser PW, Azziz R, Baskin LS, et al Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4133-4160
13. Vermeulen A, Ando S. Prolactin and adrenal androgen secretion. Clin Endocrinol (Oxf). 1978;8:295-303
14. Glasow A, Breidert M, Haidan A, Anderegg U, Kelly PA, Bornstein SR. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab. 1996;81:3103-3111
15. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-462
16. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6
17. Morse CB, Sammel MD, Shaunik A, et al. Performance of human chorionic gonadotropin curves in women at risk for ectopic pregnancy: Exceptions to the rules. Fertil Steril. 2012;97:101-106
18. Wang JG, Lobo RA. The complex relationship between hypothalamic amenorrhea and polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:1394-1397
19. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540
20. Melmed S, Colao A, Barkan A, et al Acromegaly Consensus Group. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab. 2009;94:1509-1517
21. Apter D. Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: Consequences for adult reproduction. Trends Endocrinol Metab. 1998;9:58-61
22. Rosenfield RL, Ghai K, Ehrmann DA, Barnes RB. Diagnosis of the polycystic ovary syndrome in adolescence: Comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000;13(suppl 5):1285-1289
23. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod. 2004;19:1039-1042
24. Olutunmbi Y, Paley K, English JC 3rd. Adolescent female acne: Etiology and management. J Pediatr Adolesc Gynecol. 2008;21: 171-176
25. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203: 201.e1-e5
26. Lucky AW, Biro FM, Daniels SR, Cedars MI, Khoury PR, Morri- son JA. The prevalence of upper lip hair in black and white girls during puberty: A new standard. J Pediatr. 2001;138:134-136
27. Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009;36:129-152
28. Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2010;23:7-10
29. Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol. 2010;24:173-183
30. Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab. 2006;20:311-330
31. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-413
32. McCartney CR, Blank SK, Prendergast KA, et al. Obesity and sex steroid changes across puberty: Evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab. 2007;92:430-436
33. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab. 1990;71:970-974
34. Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG. 2010;117:150-155
35. Bridges NA, Cooke A, Healy MJ, Hindmarsh PC, Brook CG. Standards for ovarian volume in childhood and puberty. Fertil Steril. 1993;60:456-460
36. Pawelczak M, Kenigsberg L, Milla S, Liu YH, Shah B. Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: Relationship to ultrasound features. J Pediatr Endocrinol Metab. 2012;25:983-989
37. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98:242-249
38. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: A common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95:4965-4972
39. Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009;94:4961-4970
40. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: Relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957-5962
41. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004;19:2036-2042
42. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1820-1826
43. Azziz R, Carmina E, Dewailly D, et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-4245
44. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90:3847-3853
45. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73:724-729
46. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15:24-28
47. Elting MW,Kwee J, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril. 2003;79:1154-1160
48. Legro RS, SchlaffWD,Diamond MP, et al Reproductive Medicine Network. Total testosterone assays in women with polycystic ovary syndrome: Precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010;95:5305-5313
49. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA. 2006;103: 7030-7035
50. Semple RK, Savage DB, Halsall DJ, O'Rahilly S. Syndromes of severe insulin resistance and/or lipodystrophy. In: Weiss RE, Refetoff S, eds. Genetic Diagnosis of Endocrine Diseases. London, UK: Academic Press, Elsevier, Inc.; 2010:105-115
51. Sari R, Akman A, Alpsoy E, Balci MK. The metabolic profile in patients with skin tags. Clin Exp Med. 2010;10:193-197
52. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89: 2745-2749
53. Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89: 199-204
54. Rausch ME, Legro RS, Barnhart HX, et al; for the Cooperative Multicenter Reproductive Medicine Network. Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:3458-3466
55. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol. 1981; 140:815-830
56. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210-223
57. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363-392
58. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247-254
59. Arias-Santiago S, Gutiérrez-Salmerón MT,Castellote- Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study. J Am Acad Dermatol. 2010;63:420-429
60. Matilainen V, Laakso M, Hirsso P, Koskela P, Rajala U, Keinänen- Kiukaanniemi S. Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study. J Cardiovasc Risk. 2003;10(3):227-231
61. Ekmekci TR, Ucak S, Basat O, Koslu A, Altuntas Y. The presence of insulin resistance and comparison of various insulin sensivity indices in women with androgenetic alopecia. Eur J Dermatol. 2007;17(1):21-25
62. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: Retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88:32-45
63. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-191
64. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril. 1963;14:631-653
65. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients.Hum Reprod. 1995;10:2107-2111
66. Bhattacharya S, Porter M, Amalraj E, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod. 2009;24: 3096-3107
67. Hull MG. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies. Gynecol Endocrinol. 1987;1:235-245
68. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83:2361-2365
69. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626-1632
70. Hudecova M, Holte J, Olovsson M, Sundström Poromaa I. Longterm follow-up of patients with polycystic ovary syndrome: Reproductive outcome and ovarian reserve. Hum Reprod. 2009;24: 1176-1183
71. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril. 1994;62: 353-362
72. Wood JR, Dumesic DA, Abbott DH, Strauss JF 3rd. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab. 2007;92:705-713
73. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod. 2002;66:297-304
74. Gregory CW, Wilson EM, Apparao KB, et al. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab. 2002;87: 2960-2966
75. Bolúmar F, Olsen J, Rebagliato M, Sáez-Lloret I, Bisanti L. Body mass index and delayed conception: A European multicenter study on infertility and subfecundity. Am J Epidemiol. 2000;151:1072-1079
76. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-566
77. Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben- Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril. 1993;60:858-863
78. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: International consensus definitions. Hum Reprod Update. 2003;9:505-514
79. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13-21
80. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1143-1150
81. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:226-229
82. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003;18:1438-1441
83. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12: 673-683
84. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. Endocr Dev. 2008;13:145-158
85. Ortega HH, Rey F, Velazquez MM, Padmanabhan V. Developmental programming: Effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod. 2010;82:1065-1075
86. Recabarren SE, Padmanabhan V, Codner E, et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab. 2005;289:E801-E806
87. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994;79:1328-1333
88. Ghizzoni L, Virdis R, Vottero A, et al. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1996;81:601-606
89. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: Possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573-2579
90. Hickey M, Sloboda DM, Atkinson HC, et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: A prospective cohort study. J Clin Endocrinol Metab. 2009;94:3714-3720
91. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr. 2000;71(5 suppl):1344S-1352S
92. Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod. 2005;20:2122-2126
93. IbáñezL, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, De Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: Insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab. 2002;87:5702-5705
94. Diamanti-Kandarakis E, Christakou C, Palioura E, Kandaraki E, Livadas S. Does polycystic ovary syndrome start in childhood? Pediatr Endocrinol Rev. 2008;5:904-911
95. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord. 2003;27:710-715
96. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: Early markers and time course in adolescence. J Clin Endocrinol Metab. 1999;84:2691-2695
97. Azziz R. Polycystic ovary syndrome is a family affair. J Clin Endocrinol Metab. 2008;93:1579-1581
98. Recabarren SE, Smith R, Rios R, et al. Metabolic profile in sons of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:1820-1826
99. Speert H. Carcinoma of the endometrium in young women. Surg Gynecol Obstet. 1949;88:332-336
100. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow- up study. Hum Fertil Camb. 2000;3:101-105
101. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: A systematic review. Reprod Biomed Online. 2009;19:398-405
102. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327-1331
103. Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol. 1991;41:143-150
104. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribu- tion in older women: Early findings of the Iowa Women's Health Study. Cancer Res. 1989;49:6828-6831
105. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008;17:73-79
106. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: A multisite case-control study. J Chronic Dis. 1985;38:435-441
107. Weiderpass E, Gridley G, Persson I, Nyrén O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997;71:360-363
108. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: A population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276-280
109. Koss LG, Schreiber K, Oberlander SG, Moussouris HF, Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol. 1984;64:1-11
110. Dreisler E, Sorensen SS, Ibsen PH, Lose G. Value of endometrial thickness measurement for diagnosing focal intrauterine pathology inwomenwithout abnormal uterine bleeding. Ultrasound Obstet Gynecol. 2009;33:344-348
111. Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: A systematic review and meta-analysis. Obstet Gynecol. 2010;116:160-167
112. Smith RA, von Eschenbach AC, Wender R, et al ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee,ACSEndometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin. 2001;51:38-75
113. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352:1223-1236
114. YildizBO,Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93:162-168
115. Sam S, Coviello AD, Sung YA, Legro RS, Dunaif A. Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care. 2008;31:1237-1241
116. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E1088-E1096
117. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26:883-896
118. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113:1148-1159
119. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85:1319-1340
120. Stener-Victorin E, Holm G, Labrie F, Nilsson L, Janson PO, Ohlsson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab. 2010; 95:810-819
121. McCartney CR, Prendergast KA, Chhabra S, et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab. 2006;91:1714-1722
122. Nyboe Andersen A, Balen A, Platteau P, Devroey P, Helmgaard L, Arce JC. Predicting the FSH threshold dose in women with WHO Group 2 anovulatory infertility failing to ovulate or conceive on clomiphene citrate. Hum Reprod. 2008;23:1424-1430
123. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174
124. Morales AJ, Laughlin GA, BützowT, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab. 1996;81:2854-2864
125. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84: 165-169
126. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-146
127. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 2010;16:347-363
128. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48-53
129. Eriksson JG, Forsén T, Tuomilehto J, Winter PD, Osmond C, Barker DJ. Catch-upgrowth in childhood and death from coronary heart disease: longitudinal study. BMJ. 1999;318:427-431
130. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Alexandraki KI. Early onset adiposity: A pathway to polycystic ovary syndrome in adolescents? Hormones (Athens). 2007;6:210-217
131. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: Comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004;66:356-362
132. Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010;94:357-359
133. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007;87:1369-1376
134. Månsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landén M. Women with polycystic ovary syndrome are often depressed or anxious-a case control study. Psychoneuroendocrinology. 2008;33:1132-1138
135. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: A longitudinal study. Fertil Steril. 2009;91:207-212
136. Stunkard AJ, Faith MS, Allison KC. Depression and obesity. Biol Psychiatry. 2003;54:330-337
137. Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010; 25:450-456
138. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: A systematic review and meta-analysis. Obstet Gynecol. 2011;117:145-152
139. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2012;97:225-230.e2
140. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): A diagnostic meta-analysis. J Gen Intern Med. 2007;22: 1596-1602
141. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: Role of insulin resistance. J Clin Endocrinol Metab. 2001;86:517-520
142. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Medicine. 2002; 3:401-404
143. Shahar E, Redline S, Young T, et al. Hormone replacement therapy and sleep-disordered breathing.AmJ Respir Crit Care Med. 2003; 167:1186-1192
144. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:365-374
145. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384
146. Baumeister SE, VölzkeH, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 2008;134:85-94
147. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1741-1747
148. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: The role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6:236-247
149. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease inwomenwith polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5:496-501
150. Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47:412-417
151. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril. 2005;83:494-497
152. Gutierrez-Grobe Y, Ponciano-Rodríguez G, RamosMH,Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9:402- 409
153. Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25: 212-220
154. Mojiminiyi OA,Safar FH, AlRumaih H, Diejomaoh M.Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scand J Clin Lab Invest. 2010;70:554-560
155. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol. 2010;26:39-46
156. de LédinghenV, Ratziu V, Causse X, et al; Association Francaise pour l'Etude du Foie Groupe Epidemiologie et Evaluation: Association Nationale des Gastroenterologues des Hopitaux generaux de France. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol. 2006;45:592-599
157. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87:1017-1023
158. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study. J Clin Endocrinol Metab. 2005;90: 3236-3242
159. Velling Magnussen L, Mumm H, Andersen M, Glintborg D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertil Steril. 2011;96:1275-1280
160. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16:1995-1998
161. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on type 2 diabetes prevention. Diabet Med. 2007;24: 451-463
162. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005;11:126-134
163. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome-a position statement of the
164. Lundblad D, Eliasson M. Silent myocardial infarction in women with impaired glucose tolerance: The Northern Sweden MONICA study. Cardiovasc Diabetol. 2003;2:9
165. Brohall G, Schmidt C, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Association between impaired glucose tolerance and carotid atherosclerosis: A study in 64-year-old women and a meta-analysis. Nutr Metab Cardiovasc Dis. 2009;19:327-333
166. Dmitrovic R, Katcher HI, Kunselman AR, Legro RS. Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome. Obstet Gynecol. 2011;118:878-885
167. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS) Society. J Clin Endocrinol Metab. 2010;95:2038-2049
168. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab. 1992;75:508-513
169. Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599-604
170. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505-513
171. Wild RA, Vesely S, Beebe L, Whitsett T, Owen W. Ferriman Gallwey self-scoring I: Performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4112-4114
172. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: A sign of a pre-hypertensive state? Hum Reprod. 1996; 11:23-28
173. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86:66-71
174. Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:6061-6067
175. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5454-5461
176. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2562-2568
177. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007;92:4609-4614
178. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: An observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89:3696-3701
179. Yarali H, Yildirir A, Aybar F, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril. 2001;76:511-516
180. Tíras MB, Yalcìn R, Noyan V, et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod. 1999;14:1949-1952
181. Ketel IJ, Stehouwer CD, Henry RM, et al. Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity-but not a PCOS-associated phenomenon. J Clin Endocrinol Metab. 2010; 95:4566-4575
182. Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M, Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care. 2007;30:1226-1232
183. Bickerton AS, Clark N, Meeking D, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58:151-154
184. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90:5711-5716
185. Carmina E, Orio F, Palomba S, et al. Endothelial dysfunction in PCOS: Role of obesity and adipose hormones. Am J Med. 2006; 119:356.e1;e6
186. Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5088-5095
187. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normalweight women with polycystic ovary syndrome: Results of a 6-month study. J Clin Endocrinol Metab. 2005;90:6072-6076
188. Tarkun I, Cetinarslan B, Türemen E, Sahin T, Cantürk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol. 2005;153:115-121
189. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. JCEM. 2001;86:4666-4673
190. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152: 749-756
191. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96:3794-3803
192. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87:2013-2017
193. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003;108:1688-1693
194. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008;93:1276-1284
195. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005; 11;277-291
196. Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: A randomized controlled trial. J Clin Endocrinol Metab. 2008;93:420-429
197. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab. 1994;79:1277-1283
198. Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: A randomized trial. Contraception. 2009;79:111-116
199. van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol. 1987;156:918-922
200. Simon D, Senan C, Garnier P, et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: The Telecom study. Am J Obstet Gynecol. 1990;163:382-387
201. Godsland IF, Crook D, Worthington M, et al. Effects of a lowestrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism. Contraception. 1993;48:217-227
202. Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.Acomparative metabolic study of two low-estrogendose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol. 1993;169:1183-1189
203. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2009;4:CD006133
204. Rimm EB, Manson JE, Stampfer MJ, et al. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia. 1992;35:967-972
205. Skouby SO, Endrikat J, Düsterberg B, et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception. 2005;71:111-117
206. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280: 533-538
207. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA. 1994;271:1099-1102
208. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiolcyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab. 2003;88:148-156
209. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: A randomized controlled study. Hum Reprod. 2002;17:1729-1737
210. Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance inwomenwith polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621-3625
211. Domecq JP, Prutsky G, Mullan R, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2385
212. American Diabetes Association. Preconception care of women with diabetes. Diabetes Care. 2003;26(Suppl 1):S91-S93
213. Frempong BA, Ricks M, Sen S, Sumner AE. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab. 2008;93:2097-2103
214. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79:15-23
215. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69.271-278
216. Akerlund M, Almström E, Högstedt S, Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand. 1994;73:136-143
217. Gevers Leuven JA, Dersjant-Roorda MC, Helmerhorst FM, de Boer R, Neymeyer-Leloux A, Havekes L. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol. 1990;163:358-362
218. van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 microg/ ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999;4:27-35
219. Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril. 1991;55:877-881
220. Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamidemetformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592-1597
221. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77:919-927
222. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152:269-275
223. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299-4306
224. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo- controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril. 1971;22: 609-623
225. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: Two randomized, placebo-controlled trials. Contraception. 2001;63:297-302
226. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: Effects on weight. Cochrane Database Syst Rev. 2008;4:CD003987
227. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50:517-527
228. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Accessible at http://whqlibdoc.who.int/publications/2010/ 9789241563888-eng.pdf. 2009
229. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989;262: 2395-2401
230. Knowler WC, Barrett-Connor E, Fowler SE, et al Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403
231. Hu G, Lakka TA, Kilpeläinen TO, Tuomilehto J. Epidemiological studies of exercise in diabetes prevention. Appl Physiol Nutr Metab. 2007;32:583-595
232. Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab. 2007;32:76-88
233. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: A systematic review. Hum Reprod Update. 2011;17:171-183
234. Orio F Jr, Giallauria F, Palomba S, et al. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:2967-2971
235. Thomson RL, Buckley JD, Moran LJ, et al. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG. 2009;116:1242-1250
236. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol. 2009;297:R387-R395
237. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:2579-2586
238. Palomba S, Falbo A, Orio F Jr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2009;92:1646-1658
239. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93:3373-3380
240. Florakis D, Diamanti-Kandarakis E, Katsikis I, et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: A randomized, 24-week study. Int J Obes (Lond). 2008;32:692-699
241. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005;90:6364-6369
242. Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164:53-60
243. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36:105-111
244. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:812-819
245. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998;13:1502-1505
246. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: Parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet.Hum Reprod. 2003;18:1928-1932
247. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470-1474
248. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21: 80-89
249. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin forwomenwith PCOS undergoing IVF treatment.Hum Reprod. 2006;21:1416-1425
250. Domecq JP, Prutsky G, Mullan R, et al. Adverse effects of common treatments for polycystic ovary syndrome: A systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi:10.1210/jc.2013-2374
251. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;7:CD007506
252. Teede HJ, Misso ML, Deeks AA. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Australia. 2011;195:S65-S112
253. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4116-4123
254. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;1: CD003053
255. Nieuwenhuis-Ruifrok AE, KuchenbeckerWK,HoekA, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive agewhoare overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009;15:57-68
256. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27:1437-1446
257. Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertil Steril. 2011;95:1059-1066.e1;e7
258. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-1880
259. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab. 2000;85:3161-3168
260. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009;32:1583-1588
261. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulinsensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;1:CD005552
262. Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90: 4068-4074
263. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: Randomised double blind clinical trial. BMJ. 2006;332:1485
264. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: A randomized controlled trial. Fertil Steril. 2009;91:514-521
265. Johnson NP, Stewart AW, Falkiner J, et al. PCOSMIC: A multicentre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Hum Reprod. 2010;25:1675-1683
266. Homburg R, Hendriks ML, König TE, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: A prospective randomized multinational study.Hum Reprod. 2012;27:468-473
267. Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: A systematic review and meta-analysis. Hum Reprod Update. 2012;18:301-312
268. NIH/NICHD Reproductive Medicine Network. Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): A randomized double- blind multicenter trial. Fertil Steril. 2013;100(3 suppl):S51
269. Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761-1765
270. Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): A multicenter, double-blind, placebocontrolled randomized trial. J Clin Endocrinol Metab. 2012;97: 1492-1500
271. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: A systematic review. Hum Reprod Update. 2007;13:527-537
272. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI inwomenwith polycystic ovary syndrome. Cochrane Database Syst Rev. 2009; 2:CD006105
273. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003-2015
274. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: A randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E448-E455
275. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: A systematic review. Gynecol Endocrinol. 2011;27:256-262
276. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: Prospective randomized trial. J Clin Endocrinol Metab. 2009;94:4938-4945
277. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril. 2004;82(Suppl 3):1193-1197
278. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth ofhumantheca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab. 2010;95:5390-5394
279. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94:103-108
280. Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial. Fertil Steril. 2011;95:1849-1852
281. Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev. 2011;10:CD008565
282. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA. 2011;305:2556-2564
283. Guttmann-Bauman I. Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the U.S.A. J Pediatr Endocrinol Metab. 2005;18:499-506
284. Hillard PJ. Oral contraceptives and the management of hyperandrogenism- polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am. 2005;34:707-723, x
285. Cedars MI. Polycystic ovary syndrome: what is it and how should we treat it? J Pediatr. 2004;144:4-6
286. Tanner JM. Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed. Philadelphia, PA: WB Saunders: 1975:14
287. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin NorthAm. 2003; 30:337-352
288. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am. 2005;34:677-705, x
289. IbáñezL, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab. 2001;86:3595-3598
290. IbáñezL, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000;85:3526-3530
291. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87:1555-1559
292. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68:209-217
293. Ladson G, Dodson WC, Sweet SD, et al. Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: A pilot randomized double-blind study. Fertil Steril. 2011; 95:2595-2598.e1;e6
294. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006;21:2252-2256
295. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005; 353:2578-2588
296. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360:606-614